同期放化疗治疗晚期口腔癌的临床效果及安全性分析  

Clinical efficacy and safety of concurrent chemoradiotherapy in the treatment of advanced oral cancer

作　　者：颜林 Yan Lin(Radiation Treatment Room,West Area of the First Affiliated Hospital of University of Science and Technology of China(Anhui Cancer Hospital),Hefei,Anhui,230031,China)

机构地区：[1]中国科学技术大学附属第一医院西区(安徽省肿瘤医院),安徽合肥230031

出　　处：《中国医学文摘（耳鼻咽喉科学）》2022年第4期107-108,111,共3页Chinese Medical Digest(Otorhinolaryngology)

摘　　要：目的 研究晚期口腔癌患者接受同期放化疗治疗的应用价值。方法 2020年2月~2021年5月,挑选在我院接受治疗的67例晚期口腔癌患者,选择掷骰法分为甲组34例、乙组33例。乙组选择序贯化放疗,甲组实行同期放化疗治疗,比较临床总有疗效以及患者1年后存活率。结果 甲乙两组总有疗效分别为94.12%、87.88%,对比数据有差异(P<0.05)。甲组1年后存活例数为31例,存活占比91.18%;乙组1年后存活例数24例,存活占比72.73%,数据间差异性显著(P<0.05)。结论 与序贯化放疗相比,晚期口腔癌患者接受同期放化疗治疗后,成效确切,1年后存活率显著提高,延长患者生存期,值得后期推广。Purpose To study the application value of concurrent radiotherapy and chemotherapy in patients with advanced oral cancer.Methods From February 2020 to may 2021,67 patients with advanced oral cancer were selected and divided into 34 cases in group A and 33 cases in group B by rolling dice.Group B was treated with sequential chemoradiotherapy,and group A was treated with concurrent chemoradiotherapy.The total clinical efficacy and the survival rate of patients after 1 year were compared.Result The total effective rates of group A and group B were 94.12% and 87.88% respectively (P < 0.05).In group A,31 cases survived after 1 year,accounting for 91.18%;In group B,24 cases survived after 1 year,accounting for 72.73%.There was significant difference between the data (P < 0.05).Conclusion Compared with sequential chemoradiotherapy,patients with advanced oral cancer after concurrent radiotherapy and chemotherapy have definite effect,the survival rate after 1 year is significantly improved,and the survival time of patients is prolonged,which is worthy of later promotion.

关 键 词：同期放化疗治疗 晚期口腔癌 临床成效 

分 类 号：R73[医药卫生—肿瘤]